Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Lila and Murray Gruber Memorial Cancer Research Award and Lectureship
Description
The Lila and Murray Gruber Memorial Cancer Research Award and Lectureship honors significant achievements in cancer research, established in 1972 in memory of Lila Gruber by her husband Murray. After Murray's passing, the award was renamed to include his legacy. The 2024 recipient is Dr. Brian Drucker, a director at the Oregon Health and Science University Knight Cancer Institute, known for his groundbreaking work translating the molecular pathogenesis of cancer into targeted therapies, notably the development of Gleevec for chronic myeloid leukemia (CML). His clinical trials dramatically increased survival rates from an average life expectancy of 3-5 years to over 95% five-year survival rates, marking a shift in cancer treatment methodologies. Dr. Drucker emphasizes the importance of understanding molecular mechanisms and the significance of patient-specific treatments. The presentation includes a meaningful testimonial from a survivor, Katie, who was treated with Gleevec just after its FDA approval; she attributes her success to Dr. Drucker’s work, illustrating the real-life impact of his research. Drucker concludes by stressing the future of cancer treatment, advocating for personalized medicine that integrates various omic analyses to better match patients with effective therapies, ultimately aiming for improved outcomes in cancer care.
View moreConclusions
- Imatinib (Gleevec) has revolutionized the treatment of chronic myeloid leukemia (CML), significantly improving survival rates from 3-5 years to a 95% five-year survival rate.
- Understanding the molecular basis of cancer, such as the BCR-ABL fusion in CML, is crucial for developing effective targeted therapies.
- Imatinib serves as a paradigm for targeted cancer treatments, shifting the focus from non-specific chemotherapy to precision medicine.
- The development of imatinib demonstrates the importance of strategic clinical trials that focus on the disease population for effective results.
- Relapses in CML are primarily due to mutations in the ABL kinase domain, prompting the development of new ABL inhibitors to combat resistance.
- Imatinib has been effective in other cancers, including gastrointestinal stromal tumors, melanoma, and dermatofibrosarcoma protuberans (DFSP).
- A successful approach to cancer treatment involves identifying key molecular targets, treating early, and utilizing precise therapies matched to patients' needs.
- Future cancer treatments will likely rely on comprehensive omic analysis and tailored therapies based on molecular profiling of individual tumors.
- Nowell, P. C., & Hungerford, D. S. (1960). A minute chromosome in human chronic granulocytic leukemia. J. Natl. Cancer Inst., 25, 85.
- B. Druker et al. (1996). Summary of Preclinical Data. Nat Med, 2:561-566, 1996.
- B. Druker et al. (2001). Phase I Clinical Trials of Imatinib. N Engl J Med, 344:1031.
- Druker et al. (2006). Overall Survival on Imatinib. NEJM, 355:2408.
- Gleich, G. J., Leiferman, K. M., Pardanani, A., Tefferi, A., & Butterfield, J. H. (2002). Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet, 359:1577-1578.
- Cools, J. et al. (2003). A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. New England Journal of Medicine, 348(13).
- Hochhaus, A. et al. (2007). Relapses and Disease Progression. Blood, 110, 11. Abstract 25. ASH 2007 Oral Presentation.